In one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics.

The bank has branched into underserved business lines.

Fintech startups in North Carolina utilizing a controversial new program may soon be able to bypass regulation entirely to test their products.

Venture firm Flagship Pioneering is spinning out a new startup, and it has a veritable powerhouse as its CEO: Margo Georgiadis, former president of the Americas at Google and former CEO of Ancestry.com and Mattel Inc.

Georgiadis joined Cambridge, Mass.-based Flagship in March to head up the then-stealthy startup. Now Flagship is formally launching Montai Health, which aims to treat chronic and complex diseases by using molecules found in foods, supplements and herbal medicines — natural compounds…

CVS Health Corp. has agreed to pay $5 billion over 10 years, and Walgreens agreed to pay $5.7 billion over 15 years, to multiple states, including Tennessee, to resolve allegations that they failed to properly oversee the dispensing of opioids.

A national accounting firm based in New York has acquired a smaller Maryland competitor.

Don't look for Brian Moynihan to be leaving his post at the helm of Bank of America anytime soon. That's the gist of his response to speculation that he could be in line to succeed Janet Yellen should she step down as secretary of the U.S. Treasury.